CR20160123A - Inhibidores de polimerasa hcv - Google Patents

Inhibidores de polimerasa hcv

Info

Publication number
CR20160123A
CR20160123A CR20160123A CR20160123A CR20160123A CR 20160123 A CR20160123 A CR 20160123A CR 20160123 A CR20160123 A CR 20160123A CR 20160123 A CR20160123 A CR 20160123A CR 20160123 A CR20160123 A CR 20160123A
Authority
CR
Costa Rica
Prior art keywords
hcv polymerase
polymerase inhibitors
prophylaxis
hepatitis
variables
Prior art date
Application number
CR20160123A
Other languages
English (en)
Inventor
Genadiy Kalayanov
Staffan Torssell
Horst Wähling
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160123(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of CR20160123A publication Critical patent/CR20160123A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Abstract

La invención proporciona compuestos de la fórmula:(I) en donde B es una nucleobase seleccionada de los grupos (a) a (d) y las otras variables son como se define en las reivindicaciones, los cuales son para uso en el tratamiento o profilaxis de infección por virus de hepatitis C, y aspectos relacionados.
CR20160123A 2013-09-04 2016-03-10 Inhibidores de polimerasa hcv CR20160123A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE1351026 2013-09-04
SE1351169 2013-10-03
SE1450152 2014-02-12
PCT/SE2014/051005 WO2015034420A1 (en) 2013-09-04 2014-09-02 Hcv polymerase inhibitors

Publications (1)

Publication Number Publication Date
CR20160123A true CR20160123A (es) 2016-07-20

Family

ID=52628746

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160123A CR20160123A (es) 2013-09-04 2016-03-10 Inhibidores de polimerasa hcv

Country Status (29)

Country Link
US (5) US9481703B2 (es)
EP (2) EP3041855B1 (es)
JP (2) JP6456958B2 (es)
KR (1) KR20160078337A (es)
CN (3) CN105705510B (es)
AU (2) AU2014315715B2 (es)
BR (1) BR112016004919A2 (es)
CA (1) CA2921899A1 (es)
CL (2) CL2016000493A1 (es)
CR (1) CR20160123A (es)
CY (1) CY1119587T1 (es)
DK (1) DK3041855T3 (es)
EA (1) EA028974B1 (es)
HK (2) HK1221228A1 (es)
HR (1) HRP20171435T1 (es)
HU (1) HUE036365T2 (es)
IL (2) IL244389B (es)
ME (1) ME02875B (es)
MX (1) MX2016002849A (es)
MY (1) MY177804A (es)
PH (2) PH12016500402B1 (es)
PL (1) PL3041855T3 (es)
PT (1) PT3041855T (es)
RS (1) RS56383B1 (es)
SA (1) SA516370684B1 (es)
SG (2) SG10201700647PA (es)
SI (1) SI3041855T1 (es)
UA (1) UA117375C2 (es)
WO (1) WO2015034420A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01528B (me) 2009-09-21 2014-04-20 Gilead Sciences Inc POSTUPCI l INTERMEDIJERI ZA PROIZVODNJU 1'-CIJANOKARBANUKLEOZIDIH ANALOGA
MX2013000744A (es) 2010-07-22 2013-03-07 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae.
CN110156838A (zh) * 2013-05-14 2019-08-23 北京美倍他药物研究有限公司 磷酸/膦酸衍生物及其医药用途
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
WO2015081133A2 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
EP3074399A1 (en) * 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
CN106536538A (zh) * 2014-04-24 2017-03-22 共晶制药股份有限公司 用于治疗黄病毒家族病毒和癌症的2’‑双取代核苷类似物
WO2016015638A1 (zh) * 2014-07-30 2016-02-04 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
TWI687432B (zh) * 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CN107205386B (zh) 2014-12-30 2021-07-23 美国陶氏益农公司 具有杀真菌活性的吡啶酰胺
BR112017013653A2 (pt) * 2014-12-30 2018-03-13 Dow Agrosciences Llc uso de compostos de picolinamida com atividade fungicida
BR122019026066B1 (pt) 2014-12-30 2022-01-18 Dow Agrosciences Llc Compostos de picolinamida
EP3240420A4 (en) 2014-12-30 2018-07-11 Dow Agrosciences LLC Use of picolinamide compounds with fungicidal activity
WO2016134057A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
AU2016226647A1 (en) * 2015-03-02 2017-09-21 Medivir Ab Nucleotide phosphoramidate formulation
CN107531739A (zh) * 2015-03-02 2018-01-02 美迪维尔公司 作为用于治疗丙型肝炎的hcv抑制剂的核苷酸衍生物
US10618926B2 (en) 2015-04-02 2020-04-14 Merck Sharp & Dohme Process for making phosphoramidate protected nucleoside compounds
CN107709344B (zh) * 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
JP6743135B2 (ja) * 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
WO2017040898A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040892A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040889A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040896A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040895A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
MA52371A (fr) 2015-09-16 2021-09-22 Gilead Sciences Inc Méthodes de traitement d'infections dues aux coronaviridae
CN105367505A (zh) * 2015-12-01 2016-03-02 苏利制药科技江阴有限公司 一种新型合成3,6-二甲基-2,5-哌嗪二酮的方法
US20190185507A1 (en) * 2016-08-19 2019-06-20 Sandoz Ag Sofosbuvir Derivatives for the Treatment of Hepatitis C
CA3056072C (en) 2017-03-14 2022-08-23 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CN110636884B (zh) 2017-05-01 2022-10-04 吉利德科学公司 新结晶形式
TWI774761B (zh) 2017-05-02 2022-08-21 美商科迪華農業科技有限責任公司 用於穀物中的真菌防治之協同性混合物
TW201842851A (zh) 2017-05-02 2018-12-16 美商陶氏農業科學公司 用於穀類中的真菌防治之協同性混合物
CN110996665B (zh) 2017-05-02 2021-10-26 陶氏益农公司 无环吡啶酰胺化合物作为针对草坪草上的真菌病害的杀真菌剂的用途
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
AU2019232478A1 (en) 2018-03-09 2020-10-15 Medivir Aktiebolag Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides
MX2021004298A (es) 2018-10-15 2021-06-08 Corteva Agriscience Llc Metodos de sintesis de oxipicolinamidas.
CN109762040A (zh) * 2019-01-14 2019-05-17 歌礼生物制药(杭州)有限公司 一种核苷类ns5b聚合酶抑制剂的制备方法
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111269263A (zh) * 2020-03-09 2020-06-12 上海龙翔生物医药开发有限公司 一种瑞德西韦侧链中间体及其制备方法
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
AU2021251689A1 (en) 2020-04-06 2022-11-17 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN111848679A (zh) * 2020-04-17 2020-10-30 山东科巢生物制药有限公司 一种利用微通道反应技术合成瑞德西韦的方法
JP2023528810A (ja) 2020-05-29 2023-07-06 ギリアード サイエンシーズ， インコーポレイテッド レムデシビル治療方法
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
EP4204421A2 (en) 2020-08-27 2023-07-05 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US20230295172A1 (en) 2022-03-02 2023-09-21 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN116199679A (zh) * 2022-12-23 2023-06-02 吉斯凯(苏州)制药有限公司 一种拉米夫定的工业化制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174992T3 (es) 1992-12-29 2002-11-16 Abbott Lab Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales.
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CN1646141B (zh) * 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
AU2007306405A1 (en) * 2006-10-10 2008-04-17 Medivir Ab HCV nucleoside inhibitor
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN102137676A (zh) 2007-12-27 2011-07-27 伊皮芬尼生物科学公司 抗病毒化合物
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
AP2011005929A0 (en) * 2009-03-20 2011-10-31 Alios Biopharma Inc Substituted nucleoside and nucleotide analogs.
CN101591371B (zh) * 2009-06-30 2012-05-30 连云港金康医药科技有限公司 一种通过卤交换氟化制备吉西他滨或其类似物的方法
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
US8402690B2 (en) 2010-09-09 2013-03-26 Sterling International Inc. Bedbug trap
KR20130110170A (ko) * 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. 치환된 뉴클레오타이드 유사체
US20120070411A1 (en) * 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
ES2702060T3 (es) 2011-12-22 2019-02-27 Alios Biopharma Inc Nucleósidos sustituidos, nucleótidos y sus análogos
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
WO2015081133A2 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
EP3074399A1 (en) * 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
CN106536538A (zh) 2014-04-24 2017-03-22 共晶制药股份有限公司 用于治疗黄病毒家族病毒和癌症的2’‑双取代核苷类似物

Also Published As

Publication number Publication date
RS56383B1 (sr) 2017-12-29
US10106571B2 (en) 2018-10-23
PH12016500402A1 (en) 2016-05-16
KR20160078337A (ko) 2016-07-04
CN108558973A (zh) 2018-09-21
EP3252066B1 (en) 2019-05-22
US20180105549A1 (en) 2018-04-19
US20190085010A1 (en) 2019-03-21
WO2015034420A1 (en) 2015-03-12
IL244389B (en) 2018-10-31
BR112016004919A2 (pt) 2017-09-05
EP3041855B1 (en) 2017-07-26
MY177804A (en) 2020-09-23
EP3041855A1 (en) 2016-07-13
SG11201601474UA (en) 2016-03-30
PL3041855T3 (pl) 2018-03-30
UA117375C2 (uk) 2018-07-25
EP3252066A1 (en) 2017-12-06
MX2016002849A (es) 2016-10-26
CN105705510A (zh) 2016-06-22
US9481703B2 (en) 2016-11-01
CL2019000271A1 (es) 2019-06-07
US20160340380A1 (en) 2016-11-24
SI3041855T1 (sl) 2017-11-30
SA516370684B1 (ar) 2017-05-10
IL261702A (en) 2018-10-31
CN108676047A (zh) 2018-10-19
JP6456958B2 (ja) 2019-01-23
US9828408B2 (en) 2017-11-28
HK1255872A1 (zh) 2019-08-30
EA028974B1 (ru) 2018-01-31
AU2017203954B2 (en) 2019-05-09
US20150175648A1 (en) 2015-06-25
HK1221228A1 (zh) 2017-05-26
JP2016529324A (ja) 2016-09-23
AU2017203954A1 (en) 2017-07-06
AU2014315715A1 (en) 2016-03-10
US20170107244A1 (en) 2017-04-20
US9540411B2 (en) 2017-01-10
PH12016500402B1 (en) 2016-05-16
CL2016000493A1 (es) 2016-12-23
CA2921899A1 (en) 2015-03-12
DK3041855T3 (en) 2017-10-23
IL261702B (en) 2019-05-30
ME02875B (me) 2018-04-20
AU2014315715B2 (en) 2017-04-06
PT3041855T (pt) 2017-11-08
CN108676047B (zh) 2021-04-02
SG10201700647PA (en) 2017-02-27
JP2019065011A (ja) 2019-04-25
EA201690452A1 (ru) 2016-08-31
CN105705510B (zh) 2018-11-30
HRP20171435T1 (hr) 2017-11-03
IL244389A0 (en) 2016-04-21
PH12018500931A1 (en) 2019-02-04
HUE036365T2 (hu) 2018-07-30
CY1119587T1 (el) 2018-03-07

Similar Documents

Publication Publication Date Title
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
SV2017005561A (es) Metodos para tratar infecciones por el virus filoviridae
ECSP15031144A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
CR20150611A (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis por el virus de la hepatitis b
CR20150085A (es) Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
EA201690526A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
CL2016003277A1 (es) Métodos para preparar análogos de nucleótido sustituidos
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
ECSP15000435A (es) Inhibidores macrocíclicos de virus flaviviridae
EA201691440A1 (ru) Производные азепана и способы лечения инфекций гепатита в
EA201690979A1 (ru) Производные азепана и способы лечения инфекций гепатита в
CO6561783A2 (es) Inhibidores del virus flaviviridae
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
UY35873A (es) ?composiciones y métodos para el control de virus en el ácaro varroa y las abejas?.
DOP2016000278A (es) Nuevos compuestos macrocíclicos
UY34066A (es) Inhibidores del virus de la hepatitis c
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
BR112017003663A2 (pt) composto, composição, e, método para tratamento de infecção por hiv.
CL2016002361A1 (es) Compuestos derivados de azabenzofurano; composición farmacéutica, y su uso como inhibidores de la función de la proteína ns5b del hcv para el tratamiento de la hepatitis c.
CR20150060A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.